Navigation Links
Compound enhances cancer-killing properties of agent in trials
Date:6/9/2010

Adding a second agent may make a new, experimental anti-cancer drug effective against a wide range of cancers, researchers at the University of Illinois at Chicago College of Medicine have found.

A man-made compound called ARC was shown by UIC researchers in 2006 to cause tumor cells to die while leaving normal cells unharmed. ARC, an acronym for its long chemical name, resembles one of the chemical building blocks of DNA. Andrei Gartel, associate professor of molecular genetics, and coworkers found it by screening more than 2,000 compounds for their ability to inhibit a key step in the cell cycle.

Now Gartel's laboratory has found that adding ARC may greatly broaden the activity of an anti-cancer agent from Abbott Laboratories that is currently in FDA trials, making it effective in killing a wide range of cancer types.

The results are published online in the journal Molecular Cancer Therapeutics.

In the earlier study, ARC was able to induce apoptosis, or cell suicide, in cancer cells, and only did so to a much lesser extent in normal cells, said Gartel, who is also principal author on the new study.

ARC works mainly by targeting MCL-1, a member of the Bcl-2 family of cellular molecules, which protect cancer cells from the apoptosis induced by anti-cancer drugs. Gartel and his colleagues were interested in whether ARC might be able to improve the activity of Abbott's investigational drug ABT-737, which inhibits several other members of the Bcl-2 family, but not MCL-1.

ABT-737 alone is effective against some small-cell lung cancer cell lines and leukemia cells, but ineffective against other cancer cells, including renal and prostate cancer cell lines.

Gartel and his colleagues knew from other research that because MCL-1 has a protective effect, preventing apoptosis, ABT-737 was not effective in cancer cells with active MCL-1. They decided to see if ARC, which inactivates MCL-1, could work together with ABT-737 to kill a wider range of cancer cells.

"We found that we could use much smaller concentrations of both agents together and effectively target and kill a broad range of cancer cell lines," said Gartel. "This combination of agents shows tremendous synergy."

Reducing the dose can lessen side-effects of potential therapies, Gartel said.

The new study suggests that ARC may have potential as an anti-cancer agent in combination therapies with ABT-737, targeting an important cellular pathway, Gartel said.


'/>"/>

Contact: Jeanne Galatzer-Levy
jgala@uic.edu
312-996-1583
University of Illinois at Chicago
Source:Eurekalert

Related medicine news :

1. Spice Compounds May Stem Tumor Growth
2. Compound found that targets wide range of viruses
3. Quality of compounded medicines supported by new standards
4. Compounds Identified That Might Treat Nerve Diseases
5. Prenatal exposure to flame-retardant compounds affects neurodevelopment of young children
6. Marijuana Compounds Could Beat Back Brain Cancer
7. New compound improves cognitive decline, symptoms of Alzheimers disease in rodents
8. Compound shows promise against intractable heart failure
9. Sigma-Aldrich Reaches Agreement to Sell Pfizers Bioactive Small Molecule Compounds
10. Chemotherapy plus synthetic compound provides potent anti-tumor effect in pancreatic cancers
11. New pyrimidine compounds may lead to improved treatments for childhood brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 13, 2017 , ... Coveros, a leader in agile coaching ... contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile ... of Agile methodologies in a consistent and high value manner across CMS programs. ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
(Date:10/12/2017)... ... , ... The American College of Medical Informatics (ACMI) will present the 2017 ... Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is ... pioneer in the field of medical informatics, this prestigious award is presented to an ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader ... a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were ... 11, 2017. , The annual award competition recognizes editorial and design excellence across a ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy Innovations ... literacy software tool, and the Cancer Patient Education Network (CPEN), an independent professional ... announce a new strategic alliance. , As CPEN’s strategic partner, HLI will ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... Sept. 28, 2017 Hill-Rom Holdings, Inc. (NYSE: ... conference call and webcast on Friday, November 3, 2017, ... and ending at approximately 8:30 a.m. (CDT) / 9:30 ... company,s 2017 financial performance and guidance for 2018, Hill-Rom ... to enhance operational performance, and long-range financial outlook through ...
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/22/2017)... , Sept. 22, 2017 AVACEN Medical (AVACEN) ... is now successfully helping those with the widespread pain ... Fibromyalgia diagnosed Amanda in Essex, England ... washing my hair, experiencing no sleep at all, tremendous ... spasm… I cannot recommend [the AVACEN 100] enough, how ...
Breaking Medicine Technology: